← Back to Clinical Trials
Recruiting NCT04883905
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Trial Parameters
Condition Acute Hepatic Porphyria
Sponsor Alnylam Pharmaceuticals
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 12 Years
Max Age N/A
Start Date 2021-04-26
Completion 2027-04-01
Brief Summary
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Eligibility Criteria
Inclusion Criteria: * Documented diagnosis of AHP, per physician's determination Exclusion Criteria: * Currently enrolled in a clinical trial for any investigational agent